论文部分内容阅读
目的分析不同临床病理因素对肝细胞癌患者血清蛋白质指纹图谱的影响。方法收集112例肝细胞癌患者血清,采用弱阳离子交换蛋白质芯片为检测介质,经表面加强激光解吸电离-飞行时间-质谱测定得到蛋白质指纹图谱,分别以性别、甲胎蛋白、门静脉癌栓、肿瘤大小、肿瘤数目、肝硬化等病理特征分组,通过B ioM arker W izard Software比较各组间血清蛋白质组分的差异。结果在质荷比为1100~30 000范围内,112例肝细胞癌的血清蛋白指纹图谱中,共检测出100个有意义的蛋白峰。(1)比较肿瘤数目:单发与多发组(≥2),16个蛋白峰差异有统计学意义(P<0.01)。(2)比较肿瘤最大直径:>3 cm与≤3 cm组,仅1个蛋白峰差异有统计学意义;>5 cm与≤5 cm组,4个蛋白峰差异有统计学意义;>10 cm与≤10 cm组,3个蛋白峰差异有统计学意义(P<0.01)。(3)比较门静脉肉眼癌栓组与无门静脉癌栓组:16个蛋白峰差异有统计学意义;比较门静脉镜下癌栓组与无门静脉癌栓组:仅2个蛋白峰差异有统计学意义;比较门静脉肉眼癌栓组与门静脉镜下癌栓组:8个蛋白峰差异有统计学意义(P<0.01)。(4)按性别、肝硬化和甲胎蛋白分组比较,血清蛋白指纹图谱没有明显差异。结论门静脉癌栓、肿瘤数目、肿瘤大小是影响肝细胞癌患者血清蛋白质指纹图谱的重要因素,而性别、肝硬化、甲胎蛋白对血清蛋白质指纹图谱没有明显影响;门静脉肉眼癌栓对血清蛋白质指纹图谱影响明显大于镜下癌栓;肿瘤大小以5 cm分界对血清蛋白质指纹图谱影响最大。
Objective To analyze the influence of different clinicopathological factors on serum protein fingerprints of patients with hepatocellular carcinoma. Methods Serum samples were collected from 112 patients with hepatocellular carcinoma. The protein fingerprints were obtained by surface-enhanced laser desorption ionization-time of flight mass spectrometry (MS / MS) with weak cation-exchange protein chip as detection medium. Size, number of tumors, cirrhosis and other pathological features were grouped by the BioMarkers Wizzard Software to compare the difference between the serum protein components. RESULTS: In the serum protein fingerprinting of 112 hepatocellular carcinoma with a mass-to-charge ratio of 1100-30 000, a total of 100 significant protein peaks were detected. (1) Compare the number of tumors: single and multiple groups (≥ 2), 16 protein peak difference was statistically significant (P <0.01). (2) Compared with the maximum diameter of tumors:> 3 cm and <3 cm groups, only one protein peak had significant difference;> 5 cm and <5 cm groups, the difference of four protein peaks was statistically significant> 10 cm And ≤10 cm group, the difference of three protein peaks was statistically significant (P <0.01). (3) Comparison of portal vein tumor thrombus group and no portal vein tumor thrombosis group: 16 protein peak difference was statistically significant; comparison of portal vein thrombosis group and no portal vein tumor thrombus group: only 2 protein peak difference was statistically significant Comparing the portal vein tumor thrombus group and the portal vein tumor thrombus group, the differences of 8 protein peaks were statistically significant (P <0.01). (4) By sex, cirrhosis and alpha-fetoprotein group comparison, serum protein fingerprinting no significant difference. Conclusions Portal vein tumor thrombus, number of tumor and tumor size are the important factors influencing the serum protein fingerprints of patients with hepatocellular carcinoma, while sex, cirrhosis and alpha-fetoprotein have no significant effect on serum protein fingerprints; portal vein tumor thrombus has no significant effect on serum protein fingerprinting Atlas of tumor size was significantly larger than that of microscopic tumor thrombus; the boundary of 5 cm in tumor size had the strongest influence on the fingerprint of serum protein.